Navigation Links
MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations
Date:7/1/2009

    MDS Pharma Services to Focus on the Delivery of Early Stage Services -
    Discovery Through Phase IIa

TORONTO, July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Phase II-IV operations to INC Research,(R) Inc.

Under the terms of the agreement, INC Research, a leading global provider of contract research organization services headquartered in Raleigh, North Carolina, has acquired MDS Pharma Services Phase II-IV operations, which includes approximately 800 employees who conduct large, multi-site clinical trials in more than 25 countries.

"The completion of this transaction supports our efforts to advance MDS Pharma Services' top-three leadership position in the delivery of Early Stage services," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc.

MDS expects to provide additional detail with respect to the divestiture of its Phase II-IV operations when the Company reports financial results for its fiscal third quarter (three months ending July 31, 2009).

The Company's decision to sell its MDS Pharma Services Late Stage operations, which are comprised of Phase II-IV operations and Central Labs, are a result of MDS's ongoing strategic review process.

A suitable buyer is being sought for Central Labs, which conducts analysis of clinical-trial samples to monitor safety and to test for physiological impact. Central Labs has more than 600 employees at six sites in Europe, North America and Asia.

MDS Pharma Services' New Strategic Focus

Additional background materials pertaining to the new strategic focus for MDS Pharma Services can be found on MDS Inc.'s Website at www.mdsinc.com/for_media/electronic_media_kit.asp

About INC Research,(R) Inc.

INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process(R) methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis Completes $15 Million Equity Financing From New and Existing Investors
2. CEL-SCI Completes $5.85 Million Registered Direct Offering
3. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
4. BioMed Realty Trust Completes $350 Million Financing for Center for Life Science Boston
5. Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology
6. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
7. NeuroTherm Completes Acquisition of the Micron Epidural Catheter
8. Homefront Diabetic Services Completes Accreditation with ACHC
9. STAAR Surgical Completes Common Stock Offering
10. SETO Holdings, Inc. Completes Agreement to Acquire Advanced Hearing Centers, Inc. and Has Disposed of All Existing Business; New Management has been installed
11. Inspire Medical Systems Completes $17 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... 2016 Mitsubishi Tanabe Pharma Corporation (Head Office: ... CEO: Dr. Masayuki Mitsuka ) has presented data ... edaravone intravenously in 10-14 day cycles for 48 weeks ... ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented ... in Dublin, Ireland . ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
Breaking Medicine Technology: